Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group CRC.3 (ECOG 5202) -- A Randomized Phase III Study Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers -- was closed to further accrual effective 11 February 2011 at 5pm EST.